MX2018000285A - Composicion para desobstruir la nariz congestionada que tiene actividad antiviral. - Google Patents
Composicion para desobstruir la nariz congestionada que tiene actividad antiviral.Info
- Publication number
- MX2018000285A MX2018000285A MX2018000285A MX2018000285A MX2018000285A MX 2018000285 A MX2018000285 A MX 2018000285A MX 2018000285 A MX2018000285 A MX 2018000285A MX 2018000285 A MX2018000285 A MX 2018000285A MX 2018000285 A MX2018000285 A MX 2018000285A
- Authority
- MX
- Mexico
- Prior art keywords
- composition
- nose
- adjusting agent
- osmolality adjusting
- disobstruge
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 6
- 230000000840 anti-viral effect Effects 0.000 title abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 3
- 208000036142 Viral infection Diseases 0.000 abstract 1
- ZNOZWUKQPJXOIG-XSBHQQIPSA-L [(2r,3s,4r,5r,6s)-6-[[(1r,3s,4r,5r,8s)-3,4-dihydroxy-2,6-dioxabicyclo[3.2.1]octan-8-yl]oxy]-4-[[(1r,3r,4r,5r,8s)-8-[(2s,3r,4r,5r,6r)-3,4-dihydroxy-6-(hydroxymethyl)-5-sulfonatooxyoxan-2-yl]oxy-4-hydroxy-2,6-dioxabicyclo[3.2.1]octan-3-yl]oxy]-5-hydroxy-2-( Chemical compound O[C@@H]1[C@@H](O)[C@@H](OS([O-])(=O)=O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H]2OC[C@H]1O[C@H](O[C@H]1[C@H]([C@@H](CO)O[C@@H](O[C@@H]3[C@@H]4OC[C@H]3O[C@H](O)[C@@H]4O)[C@@H]1O)OS([O-])(=O)=O)[C@@H]2O ZNOZWUKQPJXOIG-XSBHQQIPSA-L 0.000 abstract 1
- 239000007864 aqueous solution Substances 0.000 abstract 1
- 229940113118 carrageenan Drugs 0.000 abstract 1
- 229920001525 carrageenan Polymers 0.000 abstract 1
- 239000000679 carrageenan Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 230000002727 hyperosmolar Effects 0.000 abstract 1
- 239000004615 ingredient Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 210000002345 respiratory system Anatomy 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/731—Carrageenans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Otolaryngology (AREA)
- Dispersion Chemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Inorganic Chemistry (AREA)
- Pulmonology (AREA)
- Biochemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
La presente invención se refiere a una composición farmacéutica que tiene una actividad de desobstrucción para nariz congestionada, caracterizada porque la composición comprende una solución acuosa hiperosmolar de un agente de ajuste de osmolalidad no iónico, opcionalmente en combinación con un agente de ajuste de osmolalidad iónico, en donde la composición además comprende iota-carragenano y/o kappa-carragenano como un ingrediente antiviral activo en una cantidad antiviral eficaz, con la condición de que la composición en su formulación listo para usarse no contiene más de un 0 a 1.5% p/v del agente de ajuste de osmolalidad iónico. La composición es útil para desobstruir la nariz tapada y para la intervención profiláctica o terapéutica de un número de infecciones virales del tracto respiratorio superior.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15176670 | 2015-07-14 | ||
| PCT/EP2016/066565 WO2017009351A1 (en) | 2015-07-14 | 2016-07-12 | Stuffy nose deblocking composition having antiviral activity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2018000285A true MX2018000285A (es) | 2018-02-19 |
| MX372625B MX372625B (es) | 2020-05-12 |
Family
ID=53717900
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018000285A MX372625B (es) | 2015-07-14 | 2016-07-12 | Composicion para desobstruir la nariz congestionada que tiene actividad antiviral |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US10660914B2 (es) |
| EP (1) | EP3370692B1 (es) |
| JP (1) | JP6774435B2 (es) |
| KR (1) | KR102628781B1 (es) |
| CN (1) | CN107847430B (es) |
| AU (1) | AU2016293004B2 (es) |
| BR (1) | BR112018000592B1 (es) |
| CA (1) | CA2992352C (es) |
| CL (1) | CL2018000033A1 (es) |
| DK (1) | DK3370692T3 (es) |
| EA (1) | EA037085B1 (es) |
| ES (1) | ES2949139T3 (es) |
| FI (1) | FI3370692T3 (es) |
| HU (1) | HUE062108T2 (es) |
| IL (1) | IL256883B (es) |
| LT (1) | LT3370692T (es) |
| MA (1) | MA43155A (es) |
| MX (1) | MX372625B (es) |
| MY (1) | MY194870A (es) |
| NZ (1) | NZ738597A (es) |
| PH (1) | PH12018500044B1 (es) |
| PL (1) | PL3370692T3 (es) |
| PT (1) | PT3370692T (es) |
| SA (1) | SA518390689B1 (es) |
| WO (1) | WO2017009351A1 (es) |
| ZA (1) | ZA201708595B (es) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201806835SA (en) * | 2016-02-17 | 2018-09-27 | Ent Tech Pty Ltd | Compositions and methods for the treatment of sinus disease and disorders |
| GB2567285A (en) * | 2017-08-07 | 2019-04-10 | Suprapharm Cc | Preparation for nasal-nasopharyngeal treatment |
| CN115484964B (zh) | 2020-03-12 | 2024-03-15 | S·D·卡利斯-希尔 | 冠状病毒感染和相关细胞因子毒性的治疗 |
| CN111437270A (zh) * | 2020-04-24 | 2020-07-24 | 瑞希(重庆)生物科技有限公司 | 一种卡拉胶鼻用即型凝胶喷雾剂及其制备方法 |
| US11013687B1 (en) | 2020-06-08 | 2021-05-25 | Amcyte Pharma, Inc. | Preventive and therapeutic treatment for COVID 19 and any other disease caused by SARS CoV 2 |
| CN111686125A (zh) * | 2020-06-18 | 2020-09-22 | 大连工业大学 | 卡拉胶在抗新型冠状病毒中的应用 |
| WO2021253643A1 (zh) * | 2020-06-18 | 2021-12-23 | 大连工业大学 | 硫酸化多糖在抗新型冠状病毒中的应用 |
| AU2020454698A1 (en) * | 2020-06-22 | 2023-02-23 | Lanvira, Llc | Personal lubricants comprising lambda-carrageenan |
| EP3939597A1 (en) * | 2020-07-16 | 2022-01-19 | Marinomed Biotech AG | Antiviral pharmaceutical composition comprising a carrageenan component |
| FR3113237B1 (fr) | 2020-08-04 | 2023-06-09 | Biopass | Produit pour le traitement de maladies virales par voie nasale |
| CN116249515A (zh) * | 2020-08-04 | 2023-06-09 | 科斯莫索弗特公司 | 用于通过鼻腔途径治疗covid-19疾病的呼吸道症状的包含甘油和卡波姆的水凝胶 |
| DE202020004186U1 (de) * | 2020-10-05 | 2020-10-21 | Christian Fleischhammel | Antiinfektive Arzneiform zur Herstellung einer Nasenspülung gegen COVID-19 |
| EP3991561A1 (en) * | 2020-10-28 | 2022-05-04 | Vepidan ApS | Antimicrobial disinfectant gel |
| GB202109888D0 (en) | 2021-07-08 | 2021-08-25 | Pollinner Ltd | Nasal spray |
| KR102720037B1 (ko) * | 2021-12-21 | 2024-10-22 | (주)메디코어 | 비강 세정제 조성물 및 그 제조방법 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2653021A1 (fr) | 1989-10-17 | 1991-04-19 | Merck Sharp & Dohme | Composition ophtalmique aqueuse liquide a transition de phase liquide-gel. |
| US6080783A (en) * | 1998-09-01 | 2000-06-27 | Gum Tech International, Inc. | Method and composition for delivering zinc to the nasal membrane |
| BRPI0517891A (pt) * | 2004-11-24 | 2008-10-21 | Medpointe Healthcare Inc | composições compreendendo azelastina e métodos de uso das mesmas |
| US20080241271A1 (en) * | 2006-11-08 | 2008-10-02 | Roman Stephen B | Foaming anti-adhesion composition |
| KR101437708B1 (ko) | 2006-12-05 | 2014-09-03 | 마리노메드 바이오테크놀로지 게엠베하 | 항바이러스 조성물과 이의 이용 방법 |
| JP4941977B2 (ja) * | 2007-04-11 | 2012-05-30 | 大蔵製薬株式会社 | ベンズイソキサゾール誘導体の経口ゼリー状医薬組成物 |
| WO2009027057A1 (en) | 2007-08-24 | 2009-03-05 | Marinomed Biotechnologie Gmbh | Antiviral composition comprising a sulfated polysaccharide |
| JP5634066B2 (ja) * | 2007-11-06 | 2014-12-03 | 三栄源エフ・エフ・アイ株式会社 | 唾液分泌促進剤 |
| FR2926218B1 (fr) * | 2008-01-10 | 2010-08-13 | Galderma Res & Dev | Composition comprenant un retinoide et du peroxyde de benzoyle disperse. |
| WO2013049538A1 (en) * | 2011-09-30 | 2013-04-04 | Mcneil-Ppc, Inc. | Allergen nasal compositions |
-
2016
- 2016-07-12 PT PT167384197T patent/PT3370692T/pt unknown
- 2016-07-12 CN CN201680039448.1A patent/CN107847430B/zh active Active
- 2016-07-12 US US15/767,273 patent/US10660914B2/en active Active
- 2016-07-12 PH PH1/2018/500044A patent/PH12018500044B1/en unknown
- 2016-07-12 NZ NZ738597A patent/NZ738597A/en unknown
- 2016-07-12 AU AU2016293004A patent/AU2016293004B2/en active Active
- 2016-07-12 MA MA043155A patent/MA43155A/fr unknown
- 2016-07-12 EP EP16738419.7A patent/EP3370692B1/en active Active
- 2016-07-12 MX MX2018000285A patent/MX372625B/es active IP Right Grant
- 2016-07-12 HU HUE16738419A patent/HUE062108T2/hu unknown
- 2016-07-12 KR KR1020187004269A patent/KR102628781B1/ko active Active
- 2016-07-12 WO PCT/EP2016/066565 patent/WO2017009351A1/en not_active Ceased
- 2016-07-12 BR BR112018000592-4A patent/BR112018000592B1/pt active IP Right Grant
- 2016-07-12 FI FIEP16738419.7T patent/FI3370692T3/fi active
- 2016-07-12 MY MYPI2017704939A patent/MY194870A/en unknown
- 2016-07-12 EA EA201890196A patent/EA037085B1/ru unknown
- 2016-07-12 PL PL16738419.7T patent/PL3370692T3/pl unknown
- 2016-07-12 DK DK16738419.7T patent/DK3370692T3/da active
- 2016-07-12 LT LTEPPCT/EP2016/066565T patent/LT3370692T/lt unknown
- 2016-07-12 CA CA2992352A patent/CA2992352C/en active Active
- 2016-07-12 ES ES16738419T patent/ES2949139T3/es active Active
- 2016-07-12 JP JP2017565990A patent/JP6774435B2/ja active Active
-
2017
- 2017-12-18 ZA ZA2017/08595A patent/ZA201708595B/en unknown
-
2018
- 2018-01-03 SA SA518390689A patent/SA518390689B1/ar unknown
- 2018-01-05 CL CL2018000033A patent/CL2018000033A1/es unknown
- 2018-01-11 IL IL256883A patent/IL256883B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2018000285A (es) | Composicion para desobstruir la nariz congestionada que tiene actividad antiviral. | |
| AR116415A2 (es) | Composiciones veterinarias orales parasiticidas que comprenden agentes activos de acción sistémica, métodos y usos de las mismas | |
| MX2022014313A (es) | Formulaciones para administracion oral de agentes activos con perfil de absorcion controlada. | |
| CL2020002252A1 (es) | Formulación oftálmica. | |
| WO2014205389A8 (en) | Nuclear transport modulators and uses thereof | |
| BR102016017090B8 (pt) | Composição tópica de baixo ph e método para aumentar a aplicação tópica de um ingrediente ativo cosmeticamente aceitável | |
| CL2016002276A1 (es) | Composiciones tópicas que comprenden un extracto de coriolus versicolor para aumentar la autoinmunidad | |
| MX383706B (es) | Composiciones de cenicriviroc y métodos para elaborarlas y usarlas. | |
| BR112019004496A2 (pt) | estabilizantes de mastócitos para tratamento de hipercitocinemia e infecção viral | |
| MX2017009699A (es) | Composicion de suspension oftalmica. | |
| MX379984B (es) | Reducción de la sensación de picazón en la piel. | |
| MX2017016096A (es) | Agente antihipertensivo. | |
| MX2017016774A (es) | Agente terapeutico para la fibrosis. | |
| MX2015012716A (es) | Composiciones para el uso en el tratamiento de trastornos oculares que usan dipiridamol. | |
| MX2017009863A (es) | Agente preventivo y/o terapeutico de enfermedad inmune. | |
| MX375356B (es) | Composiciones efectivas contra la conjuntivitis viral. | |
| MX2021015441A (es) | Formas cristalinas de cabotegravir de sodio. | |
| PH12020500246A1 (en) | Pharmaceutical compositions | |
| DOP2016000078A (es) | Formas de dosificación farmacéutica que comprenden 1-[6-(morfolin-4-il)pirimidin-4-il]-4-(1h-1,2,3-triazol-1-il)-1h-pirazol-5-olato de sodio | |
| CO2017000354A2 (es) | Desmopresina estabilizada | |
| MX391201B (es) | Uso de la cefoperazona de sodio para el tratamiento de la enfermedad de chagas como agente anti-trypanosoma cruzi. | |
| MX375012B (es) | USO DE LA FLUCOXACILINA DE SODIO PARA EL TRATAMIENTO DE LA ENFERMEDAD DE CHAGAS COMO AGENTE ANTI-Trypanosoma cruzi. | |
| CR20160177A (es) | Formas de dosificación farmacéutica que comprenden 1-[6-(morfolin-4-il) pirimidin-4-il]-4-(1h-1,2,3-triazol-1-il)1h-pirazol-5-olato de sodio | |
| PL411212A1 (pl) | Połączenie leków przeciwdrobnoustrojowych oraz probiotyku i/lub prebiotyku jako innowacyjna kompozycja farmaceutyczna | |
| UA106472U (uk) | Засіб для лікування дерматологічних захворювань |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |